title: Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).
authors.forename: E M
authors.initials: EM
authors.lastname: Ohman
authors.forename: M T
authors.initials: MT
authors.lastname: Roe
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000453:epidemiology* / Q000401:mortality*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D015340:Epidemiologic Research Design; D005060:Europe; D006801:Humans; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D013223:Statistics as Topic; D016019:Survival Analysis; D015996:Survival Rate; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
chemical_list: D000077144:Clopidogrel; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine